SCHEDULE 13D/A: Casdin Capital Boosts BioLife Solutions Stake to 18.5% Following PanThera CryoSolutions Acquisition

Casdin Capital, LLC and its affiliates have increased their beneficial ownership in BioLife Solutions, Inc. to 18.5% of outstanding common stock, primarily through shares received in BioLife's acquisition of PanThera CryoSolutions, Inc.

Summary

• Casdin Capital, LLC, Casdin Partners Master Fund, L.P., Casdin Partners GP, LLC, and Eli Casdin (collectively, the "Reporting Persons") jointly filed an Amendment No. 2 to Schedule 13D regarding their beneficial ownership in BioLife Solutions, Inc.
• As of April 7, 2025, the Reporting Persons beneficially own 8,735,159 shares of BioLife Solutions common stock, representing 18.5% of the 47,241,355 shares outstanding.
• The increase in ownership includes 27,994 shares of BioLife Solutions common stock received on April 7, 2025, in exchange for shares of PanThera CryoSolutions, Inc. common stock.
• This exchange was part of BioLife Solutions' acquisition of PanThera CryoSolutions, Inc., where BioLife purchased 90% of PanThera common shares it did not previously own for $9.3 million in cash and 241,355 shares of BioLife's common stock.
• The Reporting Persons state their purpose for acquiring the shares is for investment.
• They reserve the right to engage with BioLife's management, Board of Directors, and other shareholders regarding alternatives to maximize shareholder value, and may act in concert with others or recommend courses of action.
• No borrowed funds were used for the purchase of shares, other than working capital in the ordinary course of business.

Sentiment

Score: 6

Explanation: The document indicates a significant investor increasing their stake, which can be viewed positively as a vote of confidence. While it's a disclosure of ownership and intent rather than performance, the strategic acquisition that led to the increased stake is generally a positive signal for the company's growth trajectory.

Positives

• A significant institutional investor, Casdin Capital, has increased its stake in BioLife Solutions, potentially signaling confidence in the company's long-term prospects.
• The acquisition of PanThera CryoSolutions, Inc. by BioLife Solutions, Inc. suggests strategic growth and expansion within the cryopreservation and cell/gene therapy tools market.

Risks

• The Reporting Persons reserve the right to effect extraordinary corporate transactions, changes in the Board or management, material changes in capitalization or dividend policy, or changes in operating policies or corporate structure, which could introduce uncertainty for other shareholders.
• The Reporting Persons may dispose of their shares or enter into other transactions, which could impact share price.

Future Outlook

The Reporting Persons have acquired their shares for investment purposes and reserve the right to engage with BioLife Solutions' management and Board of Directors to explore alternatives for maximizing shareholder value. They may also act in concert with other shareholders or recommend courses of action, and retain the flexibility to dispose of shares or effect other transactions in the future.

Management Comments

• Eli Casdin serves as the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC.
• The Reporting Persons have been and may continue to be in contact with members of the Issuer's management, the Issuer's Board of Directors, other significant shareholders and others regarding alternatives that the Issuer could employ to maximize shareholder value.

Industry Context

BioLife Solutions, Inc. operates in the life sciences tools and services sector, specifically focusing on biopreservation and cell/gene therapy solutions. The acquisition of PanThera CryoSolutions, Inc. indicates a strategic move to expand or consolidate its position within the cryopreservation segment, aligning with broader industry trends of consolidation and specialized technology integration in the rapidly growing cell and gene therapy market. Casdin Capital is a prominent investment firm with a focus on life sciences, suggesting a strategic investment in a key industry player.

Related Party Transactions

• The Reporting Persons, through the Fund, received 27,994 shares of BioLife Solutions common stock in exchange for their shares of PanThera CryoSolutions, Inc. common stock, as part of BioLife Solutions' acquisition of PanThera. This implies a prior investment relationship between Casdin Capital and PanThera, making the share exchange a transaction involving a significant shareholder of the acquiring entity.

Stakeholder Impact

• Shareholders: The increased stake by a major investor like Casdin Capital could be perceived as a positive signal, potentially influencing investor confidence and share price. The investor's stated intent to maximize shareholder value suggests potential future strategic initiatives.
• Employees: The acquisition of PanThera CryoSolutions, Inc. by BioLife Solutions, Inc. may lead to integration efforts, potentially impacting employees of both entities.
• Customers/Suppliers: The acquisition could lead to an expanded product/service offering or changes in supply chain dynamics for customers and suppliers of both BioLife Solutions and PanThera CryoSolutions.

Next Steps

• The Reporting Persons may continue to engage with BioLife Solutions' management and Board of Directors.
• The Reporting Persons may recommend courses of action to management and shareholders.
• The Reporting Persons reserve the right to effect changes in corporate structure, capitalization, or dispose of shares in the future.

Key Dates

Keywords

BioLife Solutions, Casdin Capital, Schedule 13D, beneficial ownership, common stock, PanThera CryoSolutions, acquisition, investment, shareholder value, life sciences, biopreservation